Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Brain natriuretic peptide].

Takayoshi Tsutamoto1, Minoru Horie

  • 1Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Otsu 520-2192.

Rinsho Byori. the Japanese Journal of Clinical Pathology
|October 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ventricular conduction is a marker for arrhythmic risk in SCN5A-E1784K overlap sodium channel disease.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Differential responses of J waves to heart rate changes in idiopathic ventricular fibrillation and the general population in Japan.

Heart rhythm·2026
Same author

A Genome-Wide Association Study Reveals <i>Desmoglein-2</i> Predominance in Japanese Arrhythmogenic Cardiomyopathy.

Journal of arrhythmia·2026
Same author

Phenotypic Severity of <i>SCN5A</i>-Related Bradycardia Is Independent of Dominant-Negative and Coupled Gating Effects.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Long-term follow-up of patients with catecholaminergic polymorphic ventricular tachycardia related to a novel <i>CALM2</i> variant.

Journal of cardiology cases·2026
Same author

Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification.

European heart journal·2025

Brain natriuretic peptide (BNP) is a key biomarker for diagnosing and managing congestive heart failure (CHF). Elevated BNP levels predict poor prognosis in CHF patients, but rapid assays can improve emergency care and treatment outcomes.

Area of Science:

  • Cardiology
  • Biochemistry
  • Physiology

Context:

  • Neurohumoral factors play a critical role in the pathophysiology of congestive heart failure (CHF).
  • Natriuretic peptides, including atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), are released by cardiomyocytes in response to stretch.
  • These peptides are vital for cardiovascular remodeling, volume balance, and myocardial injury response.

Purpose:

  • To investigate the diagnostic and prognostic utility of natriuretic peptides in heart failure.
  • To evaluate the role of plasma BNP levels as a predictor of CHF outcomes.
  • To explore the clinical benefits of rapid BNP assays in acute dyspnea and BNP-guided heart failure management.

Summary:

  • Plasma BNP levels are independent prognostic predictors in patients with left ventricular systolic dysfunction and CHF.

Related Experiment Videos

  • Higher plasma ANP and BNP levels correlate with increased mortality in chronic CHF, indicating attenuated compensatory mechanisms.
  • BNP demonstrates greater diagnostic and management utility than ANP in CHF.
  • Rapid BNP assays facilitate improved evaluation and treatment in emergency settings, potentially reducing costs and length of stay.
  • BNP-guided heart failure treatment may decrease cardiovascular events and prolong time to first event.

    • Impact:

    • High plasma BNP levels are a significant prognostic indicator for CHF patients with left ventricular systolic dysfunction.
    • Rapid BNP testing in emergency departments can expedite diagnosis and treatment of acute dyspnea, leading to reduced costs and faster discharge.
    • BNP-guided therapy holds promise for reducing cardiovascular events and improving long-term outcomes in heart failure management.